This is a method for measuring tissue factor (TF, Factor III, tissue thromboplastin) activity in plasma by using a chromogenic substrate. As pretreatment, the euglobulin fraction of plasma was prepared by removing endogenous inhibitors and heated at 60 #{176}C for 3 mm to remove fibrinogen. This allowed us to measure the low TF activity in plasma that could not otherwise be measured. Neither phospholipids nor coagulation factors VII, IX, X, or Xa in the samples interfere. Within-run and day-to-day reproducibility were both good. The mean value obtained by this method for normal persons was 1.02 (SD 0.91) arbitrary units/L. A markedly high plasma TF activity of 20 arb. units/L or more was observed in patients with some types of disseminated intravascular coagulation.
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AddItional Keyphrasee: coagulation cancer tissue thromboplastin reference interval . disseminated intravascular coagulation Tissue factor (TF), a lipoprotein, is present in brain, lung, and blood vessels and also in placental tissue and some tumor tissues (1). It consists of an apoprotein portion, containing the antigen common to various organs, and a phospholipid portion, which is required for expression of partial thromboplastin activity (2). After cell damage, the phosphohipids of TF leak into the blood and form a complex with factor VII or Vila in the presence of Ca2t This directly activates factor X in the extrinsic pathway (3) and also factor IX (4, 5) in the intrinsic pathway (6) .
'if is considered to be involved in causing disseminated intravascular coagulation (DIC) and to play an important role in abnormal coagulation and inflammatory reaction in patients with malignant tumors (7) . In addition, its involvement also in various pathological conditions such as renal disease (8) and neurological disease (9) has been suggested.
TF has been measured in the urine (8), vascular endothelial cells (10), fibroblasts (11), monocytes (12), tumor cells (13), cerebrospinal fluid (9, 14), and amniotic fluid (15) . Although the presence of TF as TF antigen in plasma has been confirmed-i.e., the apoprotein is present in the plasma of patients during surgery (16)-there are no reports on measuring TF activity in plasma. Currently available methods for measuring TF activity involve coagulation-Quick's one-step method (17) and Nemerson's twostep method (18)-and a method involving chromogenic synthetic substrates (14) . In the present study, we measured the TF activity in plasma by using the chromogenic synthetic substrate S-2222. 
Department

Analytical Variables
Proper incubation time: To determine this, we studied the changes with time of factor Xa formation in solutions containing TF diluted 50-and 200-fold and in 120 mmol/L NaCl solution. Up to 10 mm, we observed no difference in formation of factor Xa among the three solutions. The reaction curve was linear, even for the higher-concentration TF solution. Thereafter, the slope of the curve was decreased in the case of the more highly concentrated solution of TF. Between 10 and 30 mm, the absorbance increased slightly, even for the TF-free NaC1 solution. We concluded that 10 mm is the best incubation interval for measurement of factor Xa formation. Our results were similar to those described by Hische et al. (14) .
Effects of pretreatment: The euglobulmn fraction was prepared soas to remove inhibitors in plasma and heat-treated to inactivate fibrinogen, because these factors would interfere with the measurement. We determined the amounts of inhibitors and coagulation factors in the normal plasma samples before and after such treatment. Antithrombin III, a2-plasmin inhibitor, a2-macroglobulin, a1-antitrypsin, fibrinogen, and factors H, V, and VIll-all of which were within the normal reference interval before the treatment-were decreased substantially or inactivated (Tables  1 and 2) .
We compared the TF activity before and after the euglobulin fraction treatment, using six TF concentrations in plasma, obtained by mixing nine volumes of normal plasma with one volume of various dilutions of TF solution in 120 mmoL/L NaCl. Before the treatment, the TF activity was decreased, probably owing to inhibitors, and it could not be measured in plasmas containing TF diluted eightfold or less. After the treatment, the low TF activity in the plasmas containing TF diluted eight-to 32-fold could be determined, and the measured absorbance was related to this activity (Figure 1) .
The absorbance of TF did not change after treatment at 60#{176}C for 3 mm, evidencing no decrease in the TF activity. After centrifugation, however, we saw a 25% decrease in its activity. Its mechanism remains to be clarified.
Effects of pH on preparation of the euglobulin fraction:
The pH was varied from 4.6 to 7.2 during preparation of the euglobulin fraction. The TF activity measured in the euglobulin fractions obtained from normal plasma mixed with TF solution in a ratio of 9:1 showed no significant changes within this pH range (Figure 2) . negligible effects on the TF activities.
Effects of
The A405 for factor Xa at a final concentration of 1.26 x iO units/L was 0.51 before the heat treatment, but 0.03 after the treatment in this measurement system, suggesting that, even when factor Xa is present in the sample, it is inactivated by heat treatment and so has no effect on S-2222.
We measured the TF activity in a 9:1 (by vol) mixture of a series of plasmas deficient in factors VU, IX, or X and TF and compared it with the activity in normal plasma, to evaluate the effects of each of these coagulation factors on the measurement system. The A405 was 0.700 for the normal plasma, 0.728 for the factor VU-deficient plasma, 0.617 for the factor IX-deficient plasma, and 0.731 for the factor X-deficient plasma. There was no significant difference between results for the normal plasma and any of the deficient plasmas. Evidently, factors VU, IX, or X in plasma samples do not affect the measurement system.
Normal values:
The TF activity was measured in citrated plasma samples from 20 healthy subjects. We used the same arbitrary unit of TF activity as used by Hische et al. 
Discussion
The chromogenic synthetic substrate method is generally very sensitive and specific, and effects of inhibitors and fibrinogen in the sample often can be negated by high dilution of samples. There is no measurable TF activity in H Fig. 3 . Tissue factor activity in plasma from normal controls and DIC patients The valuesfor DIC patientswereobtainedat the firstexaminations normal plasma; thus TF is considered to be released into the plasma after cell damage (19) . Even when TF activity does appear in plasma, it is very low, and thus higher dilutions of plasma are not appropriate before measurement. Therefore, as pretreatment, we removed inhibitors from plasma by preparing the euglobulin fraction and treating it with heat to avoid fibrin formation during measurement. Brain-derived TF is sensitive to heat, and a 30% decrease in the activity after treatment at 50 #{176}C for 2 h was reported (20). We heated TF derived from human placenta (rabbit-brain-derived TF for reference) at 60 #{176}C for 3 mm. No effects on TF activities of this heat treatment were observed, either in brain and placental preparations. After heating, TF was measured with the S-2222 solution to monitor the TF activity. Thus, after the above pretreatment the inhibitors antithrombin Ill and a2-plasmin inhibitor, and also a2-macroglobulin and fibrinogen were removed, and even TF activity so low as to cause no fibrin clot formation could be measured. In addition, assay of serial dilutions showed good linearity.
To evaluate the effects of other substances in the measurement system, we looked for TF activity in rabbitbrain-derived phospholipids, but found none. This supports the report that, when TF is separated into apoproteins and lipids, only the latter shows no TF activity (1).
Of the activators in plasma, factor Xa acted directly on synthetic substrate S-2222 and seemed to increase results in the measurement system. However, purified factor Xa added to the sample was completely inactivated after heating at 60#{176}C for 3 mm. Therefore, even when factor Xa is present in the plasma sample, its effects on the measurement system may be removed by pretreatment.
Excessive amounts of factors VU, IX, and X were tested in the measurement system, and these factors in plasma samples do not appear to affect the measurement system, as was confirmed by the results of our evaluation in which we used plasma lacking each coagulation factor. A significant increase in the plasma TF activity was observed in five of 10 patients (19 of 39 samples). These findings suggest that TF may be a trigger for DIC. In addition, TF can be a major index for evaluating the cause and kinetics of DIC along with changes in other coagulation and fibrinolysis factors associated with DIC.
